Medical Journals

Malignant Melanoma--diagnosis and Treatment

Authors:
  • Jacobsen Kari Dolven
  • Fosså Sophie D
  • Aamdal Steinar

From: Fagområdet medikamentell behandling Rikshospitalet-Radiumhospitalet 0310 Oslo. kari.dolven.jacobsen@radiumhospitalet.no

Tidsskrift for den Norske laegeforening

  • Publish Date: Nov 2006
  • ISSN: 0807-7096
  • Volume: 126
  • Issue: 23
  • Pages: 3094-7
  • Medium: Internet
  • Language:
  • Citation (JAMA): Jacobsen Kari Dolven, Fosså Sophie D, Aamdal Steinar, et al. Malignant Melanoma--diagnosis and Treatment. Tidsskr. Nor. Laegeforen. Nov 2006;126:3094-7

Abstract

BACKGROUND: Malignant melanoma is one of the most common forms of cancer in young adults in Norway. Early diagnosis and treatment is of vital importance for the prognosis. MATERIAL AND METHODS: The article is based on articles obtained from Medline and PubMed and from the Norwegian guidelines for the treatment of malignant melanoma. RESULTS AND INTERPRETATION: The depth of invasion of the melanoma is the most important prognostic factor. The thicker the primary tumour, the less chance there is of patient survival. Patients with a localized tumour should be controlled regularly for up to five years. Primary tumours, local recurrences and metastases should be treated by surgery whenever possible. Radical lymph node dissection should be performed in patients with regional lymph node metastases with the intention of curing the patient. There is no curative chemotherapy for metastatic disease. Dacarbazine has been the most used medication for many years. The treatment is effective for about 10 - 20 % of the patients, but the response does not last for long and the treatment does not prolong survival time. Isolated limb perfusion with melphalan and TNF-alpha (tumour necrosis factor-alpha) gives high response rates in patients with metastatic disease localised in the extremities, but the treatment is only palliative. Radiation therapy has been useful in selected patients postoperatively (e.g. after removed local recurrence) and in palliation of metastatic disease. Several clinical studies with chemotherapy, immunotherapy, vaccines and combinations are ongoing. Of preventive measures, avoiding sunburn is of particular importance.

Mesh Headings (Keywords): Adult, Combined Modality Therapy, Humans, Melanoma, Neoplasm Metastasis, Neoplasm Recurrence, Local, Prognosis, Risk Factors, Skin Neoplasms, Survival Rate


Check for Full Text / PubMed Unique Identifier (PMID): 17160112


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.